文献速递妇科肿瘤

人乳头瘤病毒循环肿瘤DNA用于宫颈癌放化疗后早期检测残留病的临床验证

Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
PubMed 文献 · J Clin Oncol · 2023-11-16

这项前瞻性多中心验证研究纳入2017至2022年接受放化疗的IB-IVA期宫颈癌患者,在基线、放化疗结束时、放化疗后4-6周和3个月采血,用dPCR和HPV-seq检测HPV循环肿瘤DNA。中位随访2.2年,70例HPV阳性宫颈癌患者中24例发生PFS事件;放化疗结束时、放化疗后4-6周和3个月dPCR可检出HPV ctDNA者2年PFS均显著更差;HPV-seq结果与dPCR相似;多变量分析中dPCR和HPV-seq可检出HPV ctDNA均与更差PFS独立相关。

要点

  • 放化疗结束时dPCR可检出HPV ctDNA者2年PFS为51%,不可检出者为77%(P = .03)。
  • 放化疗后4-6周可检出者2年PFS为15%,不可检出者为82%(P < .001)。
  • 放化疗后3个月可检出者2年PFS为24%,不可检出者为82%(P < .001)。

核心结论

  • 放化疗后持续存在HPV ctDNA与更差PFS独立相关。
  • HPV ctDNA检测最早可在放化疗结束时识别高复发风险患者,供未来治疗强化试验使用。

研究设计与样本

  • 前瞻性多中心验证研究,2017至2022年纳入接受放化疗的IB-IVA期宫颈癌患者。
  • 参与者在基线、放化疗结束时、放化疗后4-6周和放化疗后3个月采血检测HPV ctDNA水平。
  • 血浆HPV基因型特异性DNA水平用dPCR和HPV-seq两种方法定量。
  • 主要终点为2年PFS。

主要发现

  • 中位随访2.2年(范围0.5-5.5年),70例HPV阳性宫颈癌患者中发生24例PFS事件。
  • 放化疗结束时dPCR可检出HPV ctDNA者2年PFS为51%,不可检出者为77%(P = .03)。
  • 放化疗后4-6周可检出者2年PFS为15%,不可检出者为82%(P < .001)。
  • 放化疗后3个月可检出者2年PFS为24%,不可检出者为82%(P < .001)。
  • 中位至复发提前时间为5.9个月;HPV-seq结果与dPCR相似;多变量分析中dPCR和HPV-seq可检出HPV ctDNA均与更差PFS独立相关。

临床怎么用

  • 作者认为,HPV ctDNA检测可在放化疗结束时识别高复发风险患者,供未来治疗强化试验使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Most cervical cancers are caused by human papilloma virus (HPV), and HPV circulating tumor DNA (ctDNA) may identify patients at highest risk of relapse. Our pilot study using digital polymerase chain reaction (dPCR) showed that detectable HPV ctDNA at the end of chemoradiation (CRT) is associated with inferior progression-free survival (PFS) and that a next-generation sequencing approach (HPV-seq) may outperform dPCR. We aimed to prospectively validate HPV ctDNA as a tool for early detection of residual disease. METHODS: This prospective, multicenter validation study accrued patients with stage IB-IVA cervical cancer treated with CRT between 2017 and 2022. Participants underwent phlebotomy at baseline, end of CRT, 4-6 weeks post-CRT, and 3 months post-CRT for HPV ctDNA levels. Plasma HPV genotype-specific DNA levels were quantified using both dPCR and HPV-seq. The primary end point was 2-year PFS. RESULTS: With a median follow-up of 2.2 (range, 0.5-5.5) years, there were 24 PFS events among the 70 patients with HPV+ cervical cancer. Patients with detectable HPV ctDNA on dPCR at the end of CRT, 4-6 weeks post-CRT, and 3 months post-CRT had significantly worse 2-year PFS compared with those with undetectable HPV ctDNA (77% v 51%, P = .03; 82% v 15%, P < .001; and 82% v 24%, P < .001, respectively); the median lead time to recurrence was 5.9 months. HPV-seq showed similar results as dPCR. On multivariable analyses, detectable HPV ctDNA on dPCR and HPV-seq remained independently associated with inferior PFS. CONCLUSION: Persistent HPV ctDNA after CRT is independently associated with inferior PFS. HPV ctDNA testing can identify, as early as at the end of CRT, patients at high risk of recurrence for future treatment intensification trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Han K, Zou J, Zhao Z, et al. Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer. J Clin Oncol. 2023. PMID: 37972346. doi:10.1200/JCO.23.00954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。